(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
Hosted on MSN9mon
AstraZeneca to cap costs of inhalers at $35 per monthAstraZeneca (NASDAQ:AZN) plans to cap out-of-pocket costs for its inhaler medications at $35 per month following Congressional criticism of the company's pricing of the products in the US.
UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...
The news followed an investigation by POLITICO’s E&E News into climate-friendly inhalers and how drug giants are developing them to undermine competition. The pharmaceutical giant AstraZeneca ...
Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic ... improve quality of life worldwide. AstraZeneca Plc is a renowned ...
.In December 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback